Is the diagnosis of melancholia important in shaping clinical management?

Current Opinion in Psychiatry

Volumn 20, Issue 3, 2007, Pages 197-201

  Parker, Gordon ^a,b,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b BLACK DOG INSTITUTE   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; MIANSERIN; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANHEDONIA; ANOREXIA; BEHAVIOR THERAPY; CIRCADIAN RHYTHM; CLINICAL TRIAL; COGNITIVE THERAPY; DEPRESSION; DEPRESSIVE PSYCHOSIS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG RESPONSE; ELECTROCONVULSIVE THERAPY; HUMAN; INSOMNIA; MELANCHOLIA; PSYCHOMOTOR DISORDER; PSYCHOTHERAPY; REMISSION; REVIEW; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ELECTROCONVULSIVE THERAPY; HUMANS; PROGNOSIS; PSYCHOMOTOR DISORDERS; PSYCHOTHERAPY;

EID: 34247148477     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e3280ad43f0     Document Type: Review

References (16)

1. Parker G, Hadzi-Pavlovic D, Boyce P. Issues in classification: II. Classifying melancholia. In: Parker G, Hadzi-Pavlovic D, editors. Melancholia: a disorder of movement and mood. New York: Cambridge University Press; 1996 . pp. 20-37.
2. Parker G, Hadzi-Pavlovic D. Melancholia: a disorder of movement and mood. New York: Cambridge University Press; 1996.
3. Taylor MA, Fink M. Melancholia. The diagnosis, pathophysiology, and treatment of depressive illness. Cambridge: Cambridge University Press; 2006.
4. Carney MWP, Roth M, Garside RF. The diagnosis of depressive syndromes and the prediction of E.C.T. response. Br J Psychiatry 1965; 111:659-674.
5. Malhi G, Parker G, Greenwood J. Structural and functional models of depression: from sub-types to substrates. Acta Psychiatr Scand 2005; 111:94-105.
6. Spiker DG, Weiss JC, Dealy RS, et al. The pharmacological treatment of delusional depression. Am J Psychiatry 1985; 142:430-435.
7. Parker G, Roy K, Hadzi-Pavlovic D, et al. Psychotic (delusional) depression: a meta-analysis of physical treatments. J Affect Disord 1992; 24:17-24.
8. Danish University Antidepressant Group (DUAG). Citalopram. Clinical effect profile and comparison with Clomipramine: a controlled multicenter study. Psychopharmacology (Berlin) 1986; 90:131-138.
9. Danish University Antidepressant Group (DUAG). Paroxetine. A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than Clomipramine in a controlled multicenter study. J Affective Disord 1990; 18:289-299.
10. Parker G, Roy K, Wilhelm K, et al. Assessing the comparative effectiveness of antidepressant therapies: a prospective clinical practice study. J Clin Psychiatry 2001; 62:117-125.
11. Parker G, Mitchell P, Wilhelm K, et al. Are the newer antidepressant drugs as effective as established physical treatments? Results from an Australasian clinical panel review. ANZ J Psychiatry 1999; 33:874-881.
12. Parker G. Differential effectiveness of newer and older antidepressants appears mediated by an age effect on the phenotypic expression of depression. Acta Psychiatr Scand 2002; 106:168-170.
13. Hickie I, Parsonage B, Parker G. Prediction of response to electroconvulsive therapy: preliminary validation of a sign-based typology of depression. Br J Psychiatry 1990; 157:65-71.
14. Parker G, Roy K, Eyers K. Cognitive behavior therapy for depression? Choose horses for courses. Am J Psychiatry 2003; 160:825-834.
15. Parker G, Parker I, Brotchie H, et al. Interpersonal psychotherapy for depression? The need to define its ecological niche. J Affect Disord 2006; 95:1-11.
16. Parker G. Beyond major depression. Psych Med 2005; 35:467-474.